Peptide Graded

Cagrilintide

Is Cagrilintide safe?

Trial data to 68 weeks; GI effects common

BSome human evidenceIn clinical trialsas of 2026-10-27

Stomach and gut effects dominate. In REDEFINE 1, 79.6% of people on CagriSema reported nausea, vomiting, diarrhoea, constipation or abdominal pain. On placebo it was 39.9%. Most cases were mild to moderate and passed. In the phase 2 trial of cagrilintide alone, 4% of participants stopped treatment because of adverse events. Across the six diabetes trials pooled in 2026, gut side effects were 2.3 times as common as on placebo and stopping for side effects about 3 times as common. 7816

A dedicated heart study found no QT prolongation. No one has studied cagrilintide for more than 68 weeks. The amylin class has little long-term data beyond pramlintide. So questions remain about rare events, weight regain after stopping and effects on lean mass. Compounded 'cagrilintide' sold online is not the trial product. The FDA has stated it cannot lawfully be compounded. 513

Read the full Cagrilintide page

More on Cagrilintide

Citations

  1. Lau 2021, Lancet: once-weekly cagrilintide for weight management, phase 2 dose-finding trial (DOI) doi.org
  2. StatPearls: Glucagon-like peptide-1 receptor agonists and the incretin system ncbi.nlm.nih.gov
  3. Garvey 2025, NEJM: coadministered cagrilintide and semaglutide (REDEFINE 1) (DOI) doi.org
  4. ClinicalTrials.gov: standalone phase 3 trial of cagrilintide clinicaltrials.gov
  5. FDA: concerns with unapproved GLP-1 drugs used for weight loss fda.gov
  6. DailyMed: Symlin (pramlintide) label dailymed.nlm.nih.gov
  7. Lau 2021, Lancet: once-weekly cagrilintide for weight management, phase 2 trial pubmed.ncbi.nlm.nih.gov
  8. Garvey 2025, NEJM: coadministered cagrilintide and semaglutide in adults with overweight or obesity (REDEFINE 1) pubmed.ncbi.nlm.nih.gov
  9. Wilding 2021, NEJM: once-weekly semaglutide in adults with overweight or obesity (STEP 1) pubmed.ncbi.nlm.nih.gov
  10. Jastreboff 2022, NEJM: tirzepatide once weekly for the treatment of obesity (SURMOUNT-1) pubmed.ncbi.nlm.nih.gov
  11. Enebo 2021, Lancet: cagrilintide with semaglutide, phase 1b trial pubmed.ncbi.nlm.nih.gov
  12. Lancet 2025: amycretin, a unimolecular GLP-1 and amylin receptor agonist, phase 1b/2a pubmed.ncbi.nlm.nih.gov
  13. Diabetes Obes Metab 2024: cagrilintide thorough QT study pubmed.ncbi.nlm.nih.gov
  14. Lancet 2025: eloralintide, a selective amylin receptor agonist, phase 2 trial pubmed.ncbi.nlm.nih.gov
  15. Novo Nordisk Q4 2025 report (SEC filing): CagriSema submitted to the FDA sec.gov
  16. Kow 2026, Diabetes Obes Metab: efficacy and safety of CagriSema in type 2 diabetes, systematic review and Bayesian meta-analysis pubmed.ncbi.nlm.nih.gov

Reference information only, not medical advice. Drawn from the Cagrilintide article, fact-checked against the cited sources. No dosing anywhere on this site.